Literature DB >> 10522853

Cardiovascular effect of 7.5% sodium chloride-dextran infusion after thermal injury.

J T Murphy1, J W Horton, G F Purdue, J L Hunt.   

Abstract

HYPOTHESIS: Clinical study can help determine the safety and cardiovascular and systemic effects of an early infusion of 7.5% sodium chloride in 6% dextran-70 (hypertonic saline-dextran-70 [HSD]) given as an adjuvant to a standard resuscitation with lactated Ringer (RL) solution following severe thermal injury.
DESIGN: Prospective clinical study.
SETTING: Intensive care unit of tertiary referral burn care center. PATIENTS: Eighteen patients with thermal injury over more than 35% of the total body surface area (TBSA) (range, 36%-71%) were studied.
INTERVENTIONS: Eight patients (mean +/- SEM, 48.2% +/- 2% TBSA) received a 4-mL/kg HSD infusion approximately 3.5 hours (range, 1.5-5.0 hours) after thermal injury in addition to routine RL resuscitation. Ten patients (46.0% +/- 6% TBSA) received RL resuscitation alone. MAIN OUTCOME MEASURES: Pulmonary artery catheters were employed to monitor cardiac function, while hemodynamic, metabolic, and biochemical measurements were taken for 24 hours.
RESULTS: Serum troponin I levels, while detectable in all patients, were significantly lower after HSD compared with RL alone (mean +/- SEM, 0.45 +/- 0.32 vs 1.35 +/- 0.35 microg/L at 8 hours, 0.88 +/- 0.55 vs 2.21 +/- 0.35 microg/L at 12 hours). While cardiac output increased proportionately between 4 and 24 hours in both groups (from 5.79 +/- 0.8 to 9.45 +/- 1.1 L/min [mean +/- SEM] for HSD vs from 5.4 +/- 0.4 to 9.46 +/- 1.22 L/min for RL), filling pressure (central venous pressure and pulmonary capillary wedge pressure) remained low for 12 hours after HSD infusion (P = .048). Total fluid requirements at 8 hours (2.76 +/- 0.7 mL/kg per each 1% TBSA burned [mean +/- SEM] for HSD vs 2.67 +/- 0.24 mL/kg per each 1% TBSA burned for RL) and 24 hours (6.11 +/- 4.4 vs 6.76 +/- 0.75 mL/kg per each 1% TBSA burned) were similar. Blood pressure remained unchanged, and serum sodium levels did not exceed 150 +/- 2 mmol/L (mean +/- SD) in either group.
CONCLUSIONS: The absence of deleterious hemodynamic or metabolic side effects following HSD infusion in patients with major thermal injury confirms the safety of this resuscitation strategy. Postburn cardiac dysfunction was demonstrated in all burn patients through the use of cardiospecific serum markers and pulmonary artery catheter monitoring. Early administration of HSD after a severe thermal injury may reduce burn-related cardiac dysfunction, but it had no effect on the volume of resuscitation or serum biochemistry values.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10522853     DOI: 10.1001/archsurg.134.10.1091

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  A portable fiberoptic ratiometric fluorescence analyzer provides rapid point-of-care determination of glomerular filtration rate in large animals.

Authors:  Exing Wang; Daniel J Meier; Ruben M Sandoval; Vanessa E Von Hendy-Willson; Barrak M Pressler; Robert M Bunch; Mouhamad Alloosh; Michael S Sturek; George J Schwartz; Bruce A Molitoris
Journal:  Kidney Int       Date:  2011-08-31       Impact factor: 10.612

2.  Burn serum causes a CD14-dependent mitochondrial damage in primary cardiomyocytes.

Authors:  Qun S Zang; David L Maass; Jane G Wigginton; Robert C Barber; Bobbie Martinez; Ahamed H Idris; Jureta W Horton; Fiemu E Nwariaku
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-03-26       Impact factor: 4.733

3.  Cardiac mitochondrial damage and inflammation responses in sepsis.

Authors:  Qun Zang; David L Maass; Sue Jean Tsai; Jureta W Horton
Journal:  Surg Infect (Larchmt)       Date:  2007-02       Impact factor: 2.150

Review 4.  Patient-centred outcomes are under-reported in the critical care burns literature: a systematic review.

Authors:  Karthik Venkatesh; Alice Henschke; Richard P Lee; Anthony Delaney
Journal:  Trials       Date:  2022-03-04       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.